NCT01951339View on ClinicalTrials.gov

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Type 2 DiabetesCardiovascular Disease
Interventions
DRUG

Sitagliptin

100 mg sitagliptin

DRUG

Glimepiride

"Active Comparator~2mg glimepiride"

DRUG

Placebo

2 mg placebo once daily

DRUG

Placebo

100 mg placebo once daily for three months

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT01951339 - Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes | Biotech Hunter | Biotech Hunter